Erlotinib Recruiting Phase 2 Trials for Neoplasms, Brain / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

RecruitingTreatment2 IdentifierTitleDrugs
NCT02655536Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
NCT02006043Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
NCT02037997Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC